Liste des publications

  1. Sharafi, H., & Jutras-Aswad, D. (2024). Response to Hall et al.: Prescription psychostimulants for amphetamine-type stimulant use disorder – acknowledging challenges but not giving up on its potential cost-effectiveness. Addiction (Abingdon, England), 10.1111/add.16434. Advance online publication. 

  2. Bakouni, H., Haquet, L., Socias, M. E., Le Foll, B., Lim, R., Ahamad, K., Jutras-Aswad, D., & OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse (2024). Associations of Methadone and BUP/NX Dose Titration Patterns With Retention in Treatment and Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: Secondary Analysis of the OPTIMA Study. Journal of addiction medicine, 10.1097/ADM.0000000000001267. Advance online publication. 

  3. Fischer, B., Robinson, T., & Jutras-Aswad, D. (2024). Three noteworthy idiosyncrasies related to Canada’s opioid-death crisis, and implications for public health-oriented interventionsDrug and alcohol review43(2), 562–566. 

  4. Bakouni, H., Haquet, L., Socias, M. E., Le Foll, B., Lim, R., Ahamad, K., Jutras-Aswad, D., & OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse (2024). Associations of Methadone and BUP/NX Dose Titration Patterns With Retention in Treatment and Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: Secondary Analysis of the OPTIMA StudyJournal of addiction medicine18(2), 167–173. 

  5. Socias, M. E., Cui, Z., Le Foll, B., Lei, J., Stewart, S., Anand, R., & Jutras-Aswad, D. (2024). Sexually transmitted and blood-borne infection risk reduction with methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: Findings from a Canadian pragmatic randomized trial. HIV medicine, 10.1111/hiv.13636. Advance online publication. 
  6. Bastien, G., Abboud, A., McAnulty, C., Elkrief, L., Ledjiar, O., Socias, M. E., Le Foll, B., Bahji, A., Brissette, S., Marsan, S., & Jutras-Aswad, D. (2024). Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial. Journal of dual diagnosis, 1–12. Advance online publication. 
  7. McAnulty, C., Bastien, G., Ledjiar, O., Eugenia Socias, M., Le Foll, B., Lim, R., Jutras-Aswad, D., & OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse (2024). Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial. Addictive behaviors154, 108023. 
  8. Coronado-Montoya, S., Abdel-Baki, A., Crockford, D., Côté, J., Dubreucq, S., Dyachenko, A., Fischer, B., Lecomte, T., L’Heureux, S., Ouellet-Plamondon, C., Roy, M. A., Tibbo, P., Villeneuve, M., & Jutras-Aswad, D. (2024). Preferences of Young Adults With Psychosis for Cannabis-Focused Harm Reduction Interventions: A Cross-Sectional Study: Préférences des jeunes adultes souffrant de psychose pour les interventions de réduction des méfaits axées sur le cannabis : une étude transversale. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 7067437241242395. Advance online publication. 
  9. Pomey, M. P., Jutras-Aswad, D., Paquette, J., Saadi, K., Taguemout, M., Ikene, D. L., Arbour, N., Zertal, A., Fréjeau, N., Morin, D., Ouellette, J. S., Alami Marrouni, K., & Duquette, P. (2024). Perceptions and engagement of patients with chronic conditions on the use of medical cannabis: a scoping review. European journal of medical research29(1), 211. 
  1. Archambault, L., Bertrand, K., Jutras-Aswad, D., Monson, E., Touré, E. H., & Perreault, M. (2023). People with opioid use disorders: A taxonomy of treatment entrants to support the development of a profile-based approach to care. Drug and alcohol review, 10.1111/dar.13634.
  2. Brodeur, M., Roberge, P., Cotton, J. C., Monson, E., Morvannou, A., Poitras, M. E., Lacasse, A., Jutras-Aswad, D., Couturier, Y., Loignon, C., Audette-Chapdelaine, S., Auger, A. M., Bertrand, K., Dorceus, S., Simon, O., & Hudon, C. (2023). Experience of LGBTQIA2S+ populations with gambling during the COVID-19 pandemic: protocol for a mixed-methods study. BMJ
    open, 13(2), e066231

  3. Chicoine, G., Côté, J., Pepin, J., Dyachenko, A., Fontaine, G., & Jutras-Aswad, D.
    (2023). Improving the self-efficacy, knowledge, and attitude of nurses regarding concurrent disorder care: Results from a prospective cohort study of an interprofessional, videoconference-based programme using the ECHO model. International journal of mental health nursing, 32(1), 290–313. 
  4. Drouin, S., Rizkallah, É., Conus, F., Larney, S., Kaur, N., Djignefa Djade, C., &
    Jutras-Aswad, D. (2023). Association Between Markers of Vulnerability for Cannabis-Related Harms and Source of Supply: Secondary Analysis of a Representative Population Survey. Canadian journal of psychiatry. Revue canadienne de psychiatrie68(2), 109–118. 
  5. Elkrief, L., Bastien, G., McAnulty, C., Bakouni, H., Hébert, F. O., Socias, M. E., Le Foll, B., Lim, R., Ledjiar, O., Marsan, S., Brissette, S., Jutras-Aswad, D., & OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse (2023). Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study. Journal of substance use and addiction treatment, 209031. 
  6. Fischer, B., Lindner, S. R., Jutras-Aswad, D., & Hall, W. (2023). Cannabis use and
    health-related ‘harm-to-others’: Towards a conceptual framework and
    evidence-base for public health. Journal of studies on alcohol and
    drugs
    , 10.15288/jsad.22-00388.
  7. Hassan, A. N., Bozinoff, N., Jutras-Aswad, D., Socias, M.E., Stewart, S. H., Lim, R., Le Foll, B., & OPTIMA Research Group (2023). Patient Satisfaction with Standard Methadone and Flexible Buprenorphine/Naloxone Models of Care: Results from a Pragmatic Randomized Controlled Clinical Trial. Journal of Addiction Medicine, 17(1), e49-e56. 
  8. Li, J., Areal, C. C., Toffa, D.H., Citherlet, D., Deacon, C., Jutras-Aswad, D., Keezer, M.R., & Nguyen, D. K. (2023). Use of non-medical cannabis in epilepsy: A scoping review. Frontiers in neurology, 14, 1132106. 
  9. Whitehurst, D. G. T., Mah, C., Krebs, E., Enns, B., Socias, M. E., Jutras-Aswad, D., Le Foll, B., Nosyk, B., & OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse (2023). Sensitivity to change of generic preference-based instruments (EQ-5D-3L, EQ-5D-5L, and HUI3) in the context of treatment for people with prescription-type opioid use disorder in Canada. Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation, 1-13. Advance online publication. 
  10. Enns, B., Krebs, E., Whitehurst, D. G. T., Jutras-Aswad, D., Le Foll, B., Socias, M. E., Nosyk, B., & OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse (2023). Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder. Drug and alcohol dependence247, 109893. 
  11. Brodeur, M., Audette-Chapdelaine, S., Lavoie, N., Devault-Tousignant, C., Auger, A. M., Morvanou, A., Légaré, A. A., Monson, E., Jutras-Aswad, D., & Hudon, C. (2023). A call for qualitative and mixed-methods research on gambling and cannabis. Addictive behaviors reports17, 100494. 
  12. Mocanu, V., Bozinoff, N., Wood, E., Jutras-Aswad, D., Le Foll, B., Lim, R., Cheol Choi, J., Yin Mok, W., Eugenia Socias, M., & OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse (2023). Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial. Drug and alcohol dependence248, 109932.
  13. Tatar, O., Abdel-Baki, A., Dyachenko, A., Bakouni, H., Bahremand, A., Tibbo, P. G., Crockford, D., Roy, M. A., Copeland, J., Fischer, B., Lecomte, T., Côté, J., Ouellet-Plamondon, C., L’Heureux, S., Villeneuve, M., & Jutras-Aswad, D. (2023). Evaluating preferences for online psychological interventions to decrease cannabis use in young adults with psychosis: An observational study. Psychiatry research326, 115276.
  14. Bakouni, H., McAnulty, C., Tatar, O., Socias, M. E., Foll, B. L., Lim, R., Ahamad, K., Jutras-Aswad, D., & OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse (2023). Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study. The American journal on addictions, 10.1111/ajad.13439. Advance online publication.
  15. Fischer, B., Hall, W., Fidalgo, T. M., Hoch, E., Foll, B. L., Medina-Mora, M. E., Reimer, J., Tibbo, P. G., & Jutras-Aswad, D. (2023). Recommendations for Reducing the Risk of Cannabis Use-Related Adverse Psychosis Outcomes: A Public Mental Health-Oriented Evidence Review. Journal of dual diagnosis19(2-3), 71–96. 
  16. Garel, N., Greenway, K. T., Dinh-Williams, L. L., Thibault-Levesque, J., Jutras-Aswad, D., Turecki, G., Rej, S., & Richard-Devantoy, S. (2023). Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 10.1038/s41386-023-01689-y. Advance online publication . 
  17. Crepeault, H., Ti, L., Jutras-Aswad, D., Wood, E., Le Foll, B., Lim, R., Bach, P., Brar, R., & Socias, M. E. (2023). Correlates of nonfatal overdose among treatment-seeking individuals with non-heroin opioid use disorder: Findings from a pragmatic, pan-Canadian, randomized control trial. Journal of substance use and addiction treatment, 209158. Advance online publication.
  18. Bahji, A., Bastien, G., Bach, P., Choi, J., Le Foll, B., Lim, R., Jutras-Aswad, D., & Socias, M. E. (2023). The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 7067437231194385. Advance online publication.
  19. Robinson, T., Ali, M. U., Easterbrook, B., Hall, W., Jutras-Aswad, D., & Fischer, B. (2023). Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis. Psychological medicine53(9), 3858–3868.
  20. Fischer, B., Jutras-Aswad, D., & Hall, W. (2023). Outcomes associated with nonmedical cannabis legalization policy in Canada: taking stock at the 5-year mark. CMAJ : Canadian Medical Association journal = journal de l’Association medicale canadienne195(39), E1351–E1353. 
  21. Tatar, O., Abdel-Baki, A., Dyachenko, A., Bakouni, H., Bahremand, A., Tibbo, P. G., Crockford, D., Roy, M. A., Copeland, J., Fischer, B., Lecomte, T., Côté, J., Ouellet-Plamondon, C., L’Heureux, S., Villeneuve, M., & Jutras-Aswad, D. (2023). Evaluating preferences for online psychological interventions to decrease cannabis use in young adults with psychosis: An observational study. Psychiatry research326, 115276.
  22. Bakouni, H., Sharafi, H., Drouin, S., Fortin, R., Marsan, S., Brissette, S., Socias, M. E., Le Foll, B., Lim, R., & Jutras-Aswad, D. (2023). Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 7067437231210796. 
  23. Sharafi, H., Bakouni, H., McAnulty, C., Drouin, S., Coronado-Montoya, S., Bahremand, A., Bach, P., Ezard, N., Le Foll, B., Schütz, C. G., Siefried, K. J., Tardelli, V. S., Ziegler, D., & Jutras-Aswad, D. (2023). Prescription psychostimulants for the treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of randomized placebo-controlled trials. Addiction (Abingdon, England), 10.1111/add.16347. 
  24. Bakouni, H., Sharafi, H., Bahremand, A., Drouin, S., Ziegler, D., Bach, P., Le Foll, B., Schütz, C. G., Tardelli, V., Ezard, N., Siefried, K., & Jutras-Aswad, D. (2023). Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials. Drug and alcohol dependence253, 111018. Advance online publication. 
  25. Kazi, I., Chenoweth, M. J., Jutras-Aswad, D., Ahamad, K., Socias, M. E., Le Foll, B., & Tyndale, R. F. (2023). Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone. Clinical pharmacology and therapeutics, 10.1002/cpt.3112. Advance online publication. 
  26. Fischer, B., Jutras-Aswad, D., & Hall, W. (2023). Résultats associés à la politique canadienne de légalisation du cannabis pour usage à des fins récréatives: bilan après 5 ans. CMAJ : Canadian Medical Association journal = journal de l’Association medicale canadienne195(47), E1648–E1650. 
  27. Fischer, B., Robinson, T., & Jutras-Aswad, D. (2023). Three noteworthy idiosyncrasies related to Canada’s opioid-death crisis, and implications for public health-oriented interventions. Drug and alcohol review, 10.1111/dar.13796. Advance online publication. 
  28. Coronado-Montoya, S., Abdel-Baki, A., Côté, J., Crockford, D., Dubreucq, S., Fischer, B., Lachance-Touchette, P., Lecomte, T., L’Heureux, S., Ouellet-Plamondon, C., Roy, M. A., Tatar, O., Tibbo, P., Villeneuve, M., Wittevrongel, A., & Jutras-Aswad, D. (2023). Evaluation of a Cannabis Harm Reduction Intervention for People With First-Episode Psychosis: Protocol for a Pilot Multicentric Randomized Trial. JMIR research protocols12, e53094. 
  1. Archambault, L., Jutras-Aswad, D., Touré, E. H., Artunduaga, A. C., Roy, S., Barbeau, D., & Perreault, M. (2022). Profiles of Patients with Opioid Use Disorders Presenting a History of Suicidal Ideations and Attempts. Psychiatric Quarterly, 93(2), 637–650. 
  2. Bastien, G., McAnulty, C., Ledjiar, O., Socias, M. E., Le Foll, B., Lim, R., Hassan, A. N., Brissette, S., Marsan, S., Talbot, A., Jutras-Aswad, D., & OPTIMA
    Research Group within the Canadian Research Initiative in Substance Misuse
    (2022). Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial. 
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 7067437221145013. 
  3. Chênevert, D., Fournier, P.-L., Menvielle, L., Bruneau, J., Jutras-Aswad, D. & Bissonnette, A. (2022). Lockdowns and Telework: Psychological and Work-Related Consequences. Relations industrielles / Industrial Relations, 77(1), 1–28.
  4. Chicoine, G., Côté, J., Pepin, J., Boyer, L., Rouleau, G., & Jutras-Aswad, D. (2022). Experiences and perceptions of nurses participating in an interprofessional, videoconference-based educational programme on concurrent mental health and substance use disorders: a qualitative study. BMC nursing21(1), 177. 
  5. Chicoine, G., Côté, J., Pepin, J., Dyachenko, A., Fontaine, G., & Jutras-Aswad, D.
    (2023).
    Improving the self-efficacy, knowledge, and attitude of nurses regarding concurrent disorder care: Results from a prospective cohort study of an interprofessional, videoconference-based programme using the ECHO modelInternational journal of mental health nursing32(1), 290–313. 
  6. Coronado-Montoya, S., Tra, C., & Jutras-Aswad, D. (2022). Harm reduction interventions as a potential solution to managing cannabis use in people with psychosis: A call for a paradigm shift. The International journal on drug policy. 108. 103814.

  7. Côté, J., Auger, P., Pagé, G. M., Cossette, S., Coronado-Montoya, S., Fontaine, G., Chicoine, G., Rouleau, G., Genest, C., Lapierre, J., & Jutras-Aswad, D.
    (2022). Adaptation culturelle et évaluation des propriétés psychométriques préliminaires de l’échelle des stratégies de protection comportementale liées à la consommation de cannabis. Canadian journal of psychiatry. Revue canadienne de psychiatrie67(8), 608–615. 
  8. Côté, J., Cossette, S., Auger, P., Page, G., Coronado-Montoya, S., Fontaine, G., Chicoine, G., Rouleau, G., Genest, C., Lapierre, J., Pedersen, E. R., & Jutras-Aswad, D. (2022). Psychometric properties of the French and English short form of the Protective Behavioural Strategies for Marijuana Scale in Canadian university students. BMJ Open, 12(4), e053715.
  9. Daldegan-Bueno, D., Maia, L. O., Glass, M., Jutras-Aswad, D., & Fischer, B. (2022). Co-exposure of cannabinoids with amphetamines and biological, behavioural and health outcomes: a scoping review of animal and human studies. Psychopharmacology239(5), 1211–1230. 
  10. Drouin, S., Rizkallah, É., Conus, F., Larney, S., Kaur, N., Djignefa Djade, C., &
    Jutras-Aswad, D. (2023).
    Association
    Between Markers of Vulnerability for Cannabis-Related Harms and Source of
    Supply: Secondary Analysis of a Representative Population Survey.
     
    Canadian journal of psychiatry. Revue canadienne de psychiatrie68(2),109–118. 
  11. Fischer, B., Robinson, T., Bullen, C., Curran, V., Jutras-Aswad, D., Medina-Mora, M. E., Pacula, R. L., Rehm, J., Room, R., van den Brink, W., & Hall, W. (2022).
    Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from
    non-medical cannabis use: A comprehensive evidence and recommendations
    update.
     The International journal on drug policy99, 103381. 
  12. Garel, N., McAnulty, C., Greenway, K. T., Lesperance, P., Miron, J. P., Rej, S., Richard-Devantoy, S., & Jutras-Aswad, D. (2022). Efficacy of ketamine intervention to decrease alcohol use, cravings, and withdrawal symptoms in adults with problematic alcohol use or alcohol use disorder: A systematic review and comprehensive analysis of mechanism of actions. Drug and alcohol dependence, 239, 109606. 
  13. Guemghar, I., Pires De Oliveira Padilha, P., Abdel-Baki, A., Jutras-Aswad, D., Paquette, J., & Pomey, M. P. (2022). Social Robot Interventions in Mental Health Care and Their Outcomes, Barriers, and Facilitators: Scoping Review. JMIR Mental Health, 9(4), e36094.
  14. Hassan,A. N., Bozinoff, N., Jutras-Aswad, D., Socias, M. E., Stewart, S. H., Lim, R., Le Foll, B., & OPTIMA Research Group (2023). Patient Satisfaction With Standard Methadone and Flexible Buprenorphine/Naloxone Models of Care: Results
    From a Pragmatic Randomized Controlled Clinical Trial.
    Journal of addiction
    medicine, 17(1), e49–e56. 
  15. Huỳnh, C., Kisely, S., Rochette, L., Pelletier, R., Morrison, K. B., Li, S., Hopkin, G., Smith, M., Burchill, C., Lin, E., Asbridge, M., Jutras-Aswad, D., & Lesage, A. (2021). Measuring Substance-Related Disorders Using Canadian Administrative Health Databanks: Interprovincial Comparisons of Recorded Diagnostic Rates, Incidence Proportions and Mortality Rate Ratios. The Canadian Journal of Psychiatry, 67(2), 117–129.
  16. Jutras-Aswad, D., le Foll, B., Ahamad, K., Lim, R., Bruneau, J., Fischer, B., Rehm, J., Wild, T. C., Wood, E., Brissette, S., Gagnon, L., Fikowski, J., Ledjiar, O., Masse, B., & Socias, M. E. (2022). Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial. American Journal of Psychiatry. 
  17. Kaur, N., Bastien, G., Gagnon, L., Graham, J., Mongeau-Pérusse, V., Bakouni, H., Morissette, F., Theriault, C., Fischer, B., & Jutras-Aswad, D. (2022). Variations of cannabis-related adverse mental
    health and addiction outcomes across adolescence and adulthood: A scoping
    review.
    Frontiers in psychiatry, 13, 973988. 
  18. Mailhot-Larouche, S., Chauvette, V., Bergeron, D., Larochelle, C., Du Pont-Thibodeau, G., Wang, H., Cardinal, H., Bourdeau, I., Auger, N., Bureau, N. B. M. M., Prat, A., Jutras-Aswad, D., Madore, F., Emeriaud, G., Bahig, H., Mayrand, M. H., Tadros, R., Parent, S., Richebe, P. R. M. P., Merhi, Y., … Nguyen, D. (2022). University of Montreal’s Clinician-Investigator Program: A 10-Year Descriptive Evaluation. Clinical and investigative medicine. Medecine
    clinique et experimentale
    45(4), E1–E10. 
  19. McAnulty, C., Bastien, G., Eugenia Socias, M., Bruneau, J., Foll, B. L., Lim, R., Brissette, S., Ledjiar, O., Marsan, S., Talbot, A., Jutras-Aswad, D., & OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse (2022). Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial. Drug and alcohol dependence239, 109604. 
  20. Mongeau-Pérusse, V., Rizkallah, E., Morissette, F., Brissette, S., Bruneau, J., Dubreucq, S., Gazil, G., Trépanier, A., & Jutras-Aswad, D. (2022). Cannabidiol Effect on Anxiety Symptoms and Stress Response in Individuals With Cocaine Use Disorder. Journal of Addiction Medicine, Publish Ahead of Print.
  21. Rizkallah, E., Mongeau-Pérusse, V., Lamanuzzi, L., Castenada-Ouellet, S., Stip, E., Juteau, L. C., Brissette, S., Bruneau, J., Dubreucq, S., & Jutras-Aswad, D. (2022). Cannabidiol effects on cognition in individuals with cocaine use disorder: Exploratory results from a randomized controlled trial. Pharmacology Biochemistry and Behavior, 216, 173376.
  22. Robinson, T., Ali, M. U., Easterbrook, B., Hall, W., Jutras-Aswad, D., & Fischer, B. (2022). Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis. Psychological Medicine, 1–11. 
  23. Robinson, T., Ali, M. U., Easterbrook, B., Coronado-Montoya, S., Daldegan-Bueno, D.,
    Hall, W., Jutras-Aswad, D., & Fischer, B. (2022). Identifying
    risk-thresholds for the association between frequency of cannabis use and development of cannabis use disorder: A systematic review and meta-analysis.
     
    Drug and alcohol dependence238,
    109582. 

  24. Socias, M.E., Wood, E., Le Foll, B., Lim, R., Choi, J. C., Mok, W. Y., Bruneau, J., Rehm,
    J., Wild, T. C., Bozinoff, N., Hassan, A., Jutras-Aswad, D., & OPTIMA
    Research Group within the Canadian Research Initiative in Substance Misuse (2022). Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder:
    secondary analysis of a Canadian treatment trial.
    Addiction (Abingdon,England), 117(10), 2662–2672. 

  25. Tatar, O., Abdel-Baki, A., Wittevrongel, A., Lecomte, T.,
    Copeland, J., Lachance-Touchette, P., Coronado-Montoya, S., Côté, J., Crockford, D., Dubreucq, S., L’Heureux, S., Ouellet-Plamondon, C., Roy, M. A.,Tibbo, P. G., Villeneuve, M., & Jutras-Aswad, D. (2022). Reducing Cannabis Use in Young Adults With
    Psychosis Using iCanChange, a Mobile Health App: Protocol for a Pilot Randomized Controlled Trial (ReCAP-iCC)
    JMIR research protocols11(11), e40817. 

     

  26. Tourjman, S. V., Buck, G., Jutras-Aswad, D., Khullar, A., McInerney, S., Saraf, G.,
    Pinto, J. V., Potvin, S., Poulin, M. J., Frey, B. N., Kennedy, S. H., Lam, R.
    W., MacQueen, G., Milev, R., Parikh, S. V., Ravindran, A., McIntyre, R. S.,
    Schaffer, A., Taylor, V. H., van Ameringen, M., … Beaulieu, S. (2022). Canadian
    Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A
    Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and
    Major Depressive Disorder.
     
    Canadian
    journal of psychiatry. Revue canadienne de psychiatrie
    , 7067437221099769.  
  1.  Artenie AA, Fortier E, Sylvestre MP, Høj SB, Minoyan N, Gauvin L, Jutras-Aswad D, Bruneau J. (2021) Socioeconomic stability is associated with lower injection frequency among people with distinct trajectories of injection drug use. International Journal of Drug Policy 94:103205.
  2. Athanassiou M, Dumais A, Gnanhoue G, Abdel-Baki A, Jutras-Aswad D, Potvin S. (2021) A systematic review of longitudinal studies investigating the impact of cannabis use in patients with psychotic disorders. Expert Rev Neurother Jun 21;1-13.
  3. Bastien G, del Grande C, Dyachenko A, Kaczorowski J, Pagé MG, Brissette S, Lespérance F, Dubreucq S, Hooley P, Jutras-Aswad D. (2021) Preferences for research design and treatment of comorbid depression among patients with an opioid use disorder: a cross-sectional discrete choice experiment. Drug Alcohol Depend Jun 27;226:108857.
  4. Bertulies-Esposito B, Ouellet-Plamondon C, Jutras-Aswad D, Gagnon J, Abdel-Baki A. The impact of treatment orders for residential treatment of comorbid severe substance use disorders for youth suffering from early psychosis: a case seriesInternational Journal of Mental Health and Addiction. 19:2233-2244.
  5. Chicoine G, Côté J, Pepin J, Fontaine G, Maheu-Cadotte MA, Hong QN, Rouleau G, Ziegler D, Jutras-Aswad D. (2021). Effectiveness and experiences of the Extension Community Healthcare Outcomes (ECHO) model in developing competencies among healthcare professionals: a mixed methods systematic review protocolSystematic Reviews, 10:313.
  6. Chicoine G, Côté J, Pépin J, Pluye P, Boyer L, Fontaine G, Rouleau G, Dubreucq S, Jutras-Aswad D (2021) Impact of a videoconferencing educational programme for the management of concurrent disorders on nurses’ competency development and clinical practice: protocol for a convergent mixed methods study British Medical Journal Open 11(3):e042875.
  7. Coronado‐Montoya, S., Morissette, F., Abdel‐Baki, A., Fischer, B., Côté, J., Ouellet‐Plamondon, C., Tremblay, L., & Jutras‐Aswad, D. (2020). Preventive interventions targeting cannabis use and related harms in people with psychosis: A systematic review. Early Intervention in Psychiatry, 15(6), 1439–1453. 
  8. Côté J, Auger P,  Pagé GM, Cossette S, Coronado-Montoya S, Fontaine G, Chicoine G, Rouleau G, Genest C, Lapierre J, Jutras-Aswad D (2021) Traduction française, adaptation culturelle et évaluation des propriétés psychométriques préliminaires de l’échelle des stratégies de protection comportementales liées à la consommation de cannabis: French translation, cultural adaptation and assessment of preliminary psychometric properties of the protective behavioral strategies for marijuana scale. Canadian Journal of Psychiatry Jun 23;7067437211025216 Ahead of print.
  9. Daldegan-Bueno D, Maia LO, Glass M, Jutras-Aswad D, Fischer B. (2021). Co-exposure of cannabinoids with amphetamines and biological, behavioural and health outcomes: a scoping review of animal and human studiesPsychopharmacology, 239(5), 1211–1230.
  10. Daldegan-Bueno D, Maia LO, Glass M, Jutras-Aswad D, Fischer B. (2021). Co-exposure of cocaine and cannabinoids and its association with select biological, behavioural, and health outcomes: a systematic scoping review of multi-disciplinary studiesEuropean Neuropsychopharmacology. 51:106-131.
  11. Fischer B, Robinson T, Bullen C, Curran V, Jutras-Aswad D, Medina-Mora ME, Liccardo Pacula R, Rehm J, Room R, van den Brink W, Hall W (2021) Lower-risk cannabis use guidelines (LRCUG) for reducing health harms from non-medical cannabis use: a comprehensive evidence and recommendations update. International Journal of Drug Policy Aug 28;103381 Ahead of print. 
  12. Fortier E, Bordier Høj S, Sylvestre MP, Artenie AA, Minoyan N, Jutras-Aswad D, Grebely J, Bruneau J. (2021). Injecting frequency trajectories and hepatitis C virus acquisition: findings from a cohort of people who inject drugs in Montréal, CanadaInternational Journal of Drug Policy. 96:103439.1.   
  13. Hébert-Seropian, B., Boucher, O., Jutras-Aswad, D., & Nguyen, D. K. (2021). Uncommon case of complete loss of hunger following an isolated left insular stroke. Neurocase, 27(4), 349–353. 
  14. Huynh C, Kisely S, Rochette L, Pelletier E, Jutras-Aswad D, Larocque A, Fleury M-J, Lesage A. (2021). Using administrative health data to estimate prevalence and mortality rates of alcohol and other substance-related disorders for surveillance purposes. Drug and Alcohol Review. 40(4):662-672.
  15. Minoyan N, Bordier Høj S, Jutras-Aswad D, Vlad D, Martel-Laferrière V, Sylvestre M-P, Bruneau J. (2021) Gender-specific associations between psychological distress and injecting risk behaviours among people who inject drugs in Montreal, Canada. Int J Drug Policy Jun18;103319.
  16. Mongeau-Pérusse V, Brissette S, Bruneau J, Conrod P, Dubreucq S, Gazil G, Stip E, Jutras-Aswad D (2021) Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placebo-controlled trial. Addiction. 116(9):2431-2442.
  17. Mongeau‐Pérusse, V., & Jutras‐Aswad, D. (2020). Challenging CBD protective effect against THC‐related outcomes: a call for robust clinical trials. Addiction, 116(1), 207–208. 
  18. Mongeau-Pérusse V, Rizkallah E, Bruneau J, Chênevert D, Menvielle L, Jutras-Aswad D (2021) Changes in alcohol habits among workers during the confinement of COVID-19: results of a canadian cross-sectional survey. Substance Abuse Jul 16;15:11782218211033298.
  19. Morissette F, Mongeau-Pérusse V, Rizkallah E, Thébault P, Lepage S, Brissette S, Bruneau J, Dubreucq S, Stip E, Cailhier JF, Jutras-Aswad D. (2021). Exploring cannabidiol effects on inflammatory markers in individuals with cocaine use disorder: a randomized controlled trial. Neuropsychopharmacology. 46:2101-2111.
  20. Ouellet-Plamondon, C., Abdel-Baki, A., & Jutras-Aswad, D. (2021). Premier épisode psychotique et trouble de l’usage de substance concomitants : revue narrative des meilleures pratiques et pistes d’approches adaptées pour l’évaluation et le suivi. Santé Mentale Au Québec, 46(2), 277. 
  21. Tatar O, Abdel-Baki A, Tra C, Mongeau-Pérusse V, Arruda N, Kaur N, Landry V, Coronado-Montoya S, Jutras-Aswad D (2021) Technology-based psychological interventions for young adults with early psychosis and cannabis use disorder: qualitative study of patient and clinician perspectives. Journal of Medical Internet Research 5(4):e26562.
  1. Bertulies-Esposito B, Ouellet-Plamondon CÉ, Jutras-Aswad D, Gagnon J, Abdel-Baki A (2020) The impact of treatment orders for residential treatments of comorbid severe substance use disorders for youth suffering from early psychosis: a case series. International Journal of Mental Health and Addiction.
  2. Coronado-Montoya S, Morissette F, Abdel-Baki A, Fischer B, Côté J, Ouellette-Plamondon C, Tremblay L, Jutras-Aswad D (2020) Preventive interventions targeting cannabis use and related harms in people with psychosis: a systematic review. Early Intervention in Psychiatry Ahead of print. 
  3. Elkrief L, Belliveau J, D’Ignazio T, Simard P, Jutras-Aswad D (2020) Assessing the current state of medical education on cannabis in Canada: preliminary findings from Quebec. Paediatrics & Child Health 25(Suppl 1):S29-S33.
  4. Fortier E, Sylvestre MP, Artenie AA, Minoyan N, Jutras-Aswad D, Roy É, Grebely J, Bruneau J (2020). Associations between housing stability and injecting frequency fluctuations: findings from a cohort of people who inject drugs in Montréal, Canada. Drug Alcohol and Dependence 206 :107744.
  5. Ghabrash MF, Bahremand A, Veilleux M, Blais-Normandin G, Chicoine G, Sutra-Cole C, Kaur N, Ziegler D, Dubreucq S, Juteau LC, Lestage L, Jutras-Aswad D (2020) Depression and outcomes of methadone and buprenorphine treatment among people with opioid use disorders: a literature review. Journal of Dual Diagnosis 23 :1-17.
  6. Ghabrash MF, Coronado-Montoya S, Aoun J, Gagné AA, Mansour F, Ouellet-Plamondon C, Trépanier A, Jutras-Aswad D. (2020) Cannabidiol for the treatment of psychosis among patients with schizophrenia and other primary psychotic disorders: a systematic review with a risk of bias assessment. Psychiatry Research 286 :112890.
  7. Kaboré J-L, Dassieu L, Roy É, Jutras-Aswad D, Bruneau J, Pagé MG, Choinière M (2020) Prevalence, characteristics, and management of chronic non-cancer pain among people who use drugs: a cross-sectional study. Pain Medicine 0(0):1-10.
  8. Kaur N, Bastien G, Mongeau-Pérusse V, Graham J, Thériault C, Jutras-Aswad D (2020) Comparing mental health outcomes of cannabis use among adolescents and adults: a scoping review. Research protocole registered at Open Science Framework
  9. Minoyan N, Artenie AA, Zang G, Jutras-Aswad D, Turcotte ME, Bruneau J (2020) Harm reduction coverage and hepatitis C incidence: findings from a cohort of people who inject drugs. American Journal of Preventive Medicine 58(6):845-853.
  10. Mongeau-Pérusse V, Jutras-Aswad D (2020) Challenging CBD protective effects against THC-related outcomes: a call for robust clinical trials. Addiction. 
  11. Ouellet-Plamondon C, Dubreucq S, Jutras-Aswad D (2020) Management of psychosis in the context of cannabis use: beyond the chicken or the egg question. Paediatrics & Child Health 25(Suppl 1):S5-S6.
  12. Sylvestre MP, Wellman RJ, Ahun MN, Datta G, Jutras-Aswad D, O Loughlin J (2020) Discrete time measures versus trajectories of drinking frequencies across adolescence as predictors of binge drinking in young adulthood: a longitudinal investigation. BMJ Open 10(9):e035939.
  13. Tatar O, Bastien G, Abdel-Baki A, Huynh C, Jutras-Aswad D. (2020) A systematic review of technology-based psychotherapeutic interventions for decreasing cannabis use in patients with psychosis. Psychiatry Research 288:112940.
  1. Artenie AA, Minoyan N, Jacka B, Høj S, Jutras-Aswad D, Roy É, Gauvin L, Zang G, Bruneau J (2019). Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs. Canadian Medical Association Journal 191(17):E462-E468.
  2. Bruneau J, Arruda N, Zang G, Jutras-Aswad D, Roy É (2019). The evolving drug epidemic of prescription opioid injection and its association with HCV transmission among people who inject drugs in Montréal, Canada. Addiction 114(2):366-373.
  3. Chabot-Doré AJ, Jutras-Aswad D, Lachance-Touchette P, Saavedra V, & Mongeau-Pérusse V. (2019) Mandat de recherche en lien avec le dossier cannabis octroyé par la Direction québécoise de la légalisation du cannabis du ministère de la Santé et des Services sociaux, Unité de recherche en psychiatrie des toxicomanies, CRCHUM.
  4. Côté P, Ghabrash MF, Bruneau J, Roy É, Dubreucq S, Fortier E, Jutras-Aswad D (2019). Association between mental health service utilisation and sharing of injection material among people who inject drugs in Montreal, Canada. Addictive Behaviors 96:175-182.
  5. Desrosiers JJ, Tchiloemba B, Boyadjieva R, Jutras-Aswad D (2019) Implementation of a contingency approach for people with co-occurring substance use and psychiatric disorders: acceptability and feasibility pilot study. Addictive Behaviors Reports. 10 :100223.
  6. Doré-Gauthier V, Côté H,  Jutras-Aswad D, Abdel-Baki A (2019). How to help homeless youth suffering from first episode psychosis and substance use disorders? The creation of a new intensive outreach intervention team Psychiatric Research 273:603-12.
  7. Doré-Gauthier V, Miron JP, Jutras-Aswad D, Ouellet-Plamondon C, Abdel-Baki A (2019). Specialized assertive community treatment intervention for homeless youth with first episode psychosis and substance use disorder: A 2-year follow-up study. Early Intervention in Psychiatry 14(2):203-10.
  8. Fortier E, Artenie AA, Zang G, Jutras-Aswad D, Roy É, Grebely J, Bruneau J (2019). Short and sporadic injecting cessation episodes as predictors of incident hepatitis C virus infection: findings from a cohort study of people who inject drugs in Montréal, Canada. Addiction 114(8) :1495-1503.
  9. Huynh C, Rochette L, Jutras-Aswad D, Larocque A, Fleury MJ, Kisely S, & Lesage A (2019) Les troubles liés aux substances psychoactives – Prévalence des cas identifiés à partir des banques de données administratives, 2001-2016. Institut national de santé publique du Québec. Bureau d’information et d’études en santé des populations, 43 pages.
  10. Jacka B, Roy É, Høj S, Minoyan N, Artenie AA, Zang G, Jutras-Aswad D, Bruneau J (2019). Sexual behaviour as a risk factor for hepatitis C virus infection among people who inject drugs in Montreal, Canada. Journal of Viral Hepatitis 26(12):1413-22.
  11. Jobidon L, El Hage C, Jutras-Aswad D. (2019) Cannabis et santé mentale.  Dans: Cannabis. Éditeurs: Les Presses de l’Université de Montréal, Sous la direction de Brochu S, Fallu JS et Pelletier M.
  12. Jutras-Aswad D, Le Foll B, Bruneau J, Wild TC, Wood E, Fischer B (2019). Thinking Beyond Legalization: The case for expanding evidence-based options for cannabis use disorder treatment in Canada. Canadian Journal of Psychiatry 64(2):82-7.
  13. Makarenko I, Artenie A, Hoj S, Minoyan N, Jacka B, Zang G, Barlett G, Jutras-Aswad D, Martel-Laferriere V, Bruneau J (2019). Transitioning from interferon-based to direct antiviral treatment options: a potential shift in barriers and facilitators of treatment initiation among people who use drugs? International Journal of Drug Policy 72:69-76.
  1. El Hage C, Ghabrash MF, Dubreucq S, Brissette S, Lespérance F, Lespérance P, Ouellet-Plamondon C, Bruneau J, Jutras-Aswad D (2018). A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder. International Clinical Psychopharmacology 33(5):268-273.
  2. Gouvernement du Québec. (2018) Plan d’action interministériel en dépendance 2018-2028 – Prévenir, réduire et traiter les conséquences associées à la consommation de substances psychoactives, à la pratique de jeux de hasard et d’argent et à l’utilisation d’Internet, 115 pages.
  3. Harris C, Jutras-Aswad D, Ware MA, Lachance-Touchette P, & Saavedra V. (2018) Rapport de recherche: Lignes directrices sur la qualité du cannabis commercialisé. Unité de recherche en psychiatrie des toxicomanies, CRCHUM, 48 pages.
  4. Juteau LC, Roy É, Berbiche D, Arruda N, Bruneau J, Jutras-Aswad D (2018). Examining the association between psychiatric disorders and cocaine binges: results from the COSMO study. Journal of Addiction Medicine 12(2):136-142.
  5. Jutras Aswad D, Ware MA, Lachance-Touchette P, Saavedra V, El Hage C & Dagenais A (2018) Rapport de recherche: Lignes directrices sur la composition du cannabis commercialisé. Unité de recherche en psychiatrie des toxicomanies, CRCHUM, 79 pages.
  6. Patenaude C, Brochu S, Fallu J-S, Jutras-Aswad D, D’Arcy L (2018). Le marché légal du cannabis suite à sa légalisation au Canada : pistes de réflexion pour un encadrement efficace. Canadian Journal of Public Health 109(2):215-218.
  7. Roy É, Arruda N, Jutras-Aswad D, Berbiche D, Motta-Ochoa R, Bruneau J (2018). Tranquilizer misuse among active cocaine users: predictors of initiation. Drug and Alcohol Review 37(4):520-6.
  8. Socias ME, Ahamad K, Le Foll B, Lim R, Bruneau J, Fischer B, Wild TC, Wood E, Jutras-Aswad D (2018) The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: study design and rationale. Contemporary Clinical Trials 69:21-7.
  9. Tremblay A, Lachance-Touchette P, Ziegler D, Bourgoin M, Trahan V, Ghabrash M, & Jutras-Aswad D (2018) Cannabinoïdes synthétiques. Unité de recherche en psychiatrie des toxicomanies, CRCHUM, 99 pages.
  1. Artenie A-A, Zang G, Daniel M, Fortier E, Jutras-Aswad D, Svetlana Puzhko, Bruneau J (2017). Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection. International Journal on Drug Policy 47:239-243.
  2. Baker, T.E., Lesperance, P., Potvin, S., Tucholka, A., Jutras-Aswad, D., Zhang, Y., Larcher, K., and Conrod, P (2017). Reversing the atypical valuation of drug and nondrug rewards in smokers using a brain-based intervention. Biological Psychiatry 82(11):819-827.
  3. Desroches J, Ware MA, Jutras-Aswad D, Lachance-Touchette P, & Saavedra V (2017) Composantes d’une formation pour les employés attitrés à la vente au détail. Unité de recherche en psychiatrie des toxicomanies, CRCHUM, 59 pages.
  4. Dufresne L, Jutras-Aswad D, Bayard, I & Châteauvert, L (2017) Rapport au comité Directeur du RUIS de l’Université de Montréal concernant la création d’un centre d’expertise en troubles concomitants. Réseau universitaire de santé intégré (RUIS), Université de Montréal, 24 pages.
  5. Fournier C, Ghabrash MF, Artenie A, Roy E, Zang G, Bruneau J, Jutras-Aswad D (2017). Association between binge drug use and suicide attempt among people who inject drugs. Substance Abuse 39(3):315-321
  6. Giasson-Gariépy K, Potvin S, Ghabrash M, Bruneau J, Jutras-Aswad, D (2017). Cannabis and cue-induced craving in cocaine-dependent individuals: A pilot study. Addictive Behaviors 73:4-8.
  7. Jobidon L, Jutras-Aswad D (2017). Le cannabis et ses effets délétères: pour un débat plus nuancé. Drogues, Santé et Société 16(1):5-30.
  8. Jutras-Aswad D. (2017) Le cannabis: prescrit, récréatif ou un peu des deux? Le Médecin du Québec 52(12).
  9. Motta-Ochoa R, Bertrand K, Arruda N, Jutras-Aswad, D, Roy É (2017). “I love having benzos after my coke shot”: The use of psychotic medication among cocaine users in downtown Montreal. International Journal of Drug Policy 49: 15-23.
  10. Ouellet-Plamondon C, Dubreucq S, Trépanier A, Jutras-Aswad D (2017). La légalisation du cannabis: opportunités et défis? Journal de l’Association des Médecins Psychiatres du Québec 52(12).
  11. Puzhko S, Roy É, Jutras-Aswad, D, Artenie A-A, Fortier E, Zhang G, Bruneau J (2017). High hepatitis C incidence in relation to prescription opioid injection and poly-drug use: assessing barriers to hepatitis C prevention. International Journal of Drug Policy 47:61-8.
  12. Roy E, Arruda N, Jutras-Aswad D, Berbiche D, Perreault M, Bertrand K, Dufour M, Bruneau J (2017). Examining the link between cocaine binging and individual, social and behavioral factors among street-based cocaine users. Addictive Behaviors 68:66-72.
  13. Socías ME, Kerr T, Wood E, Dong H, Lake S, Hayashi K, DeBeck K, Jutras-Aswad, D., Montaner J, Milloy MJ (2017). Intentional cannabis use to reduce crack cocaine use in a Canadian setting: a longitudinal analysis. Addictive Behaviors 72:138-143.
  1. Dufour M, Nguyen N, Bertrand K, Perreault M, Jutras-Aswad D, Morvannou A, Bruneau J, Berbiche D, Roy É (2016). Gambling problems among community cocaine users.  Journal of Gambling Studies 32(3):1039-53.
  2. Egervari G, Jutras-Aswad D, Landry J, Miller ML, Anderson SA, Michaelides M, Jacobs MM, Peter C, Yiannoulos G, Liu X, Hurd YL (2016). A functional 3’UTR polymorphism (rs2235749) of prodynorphin alters microRNA-365 binding in ventral striatonigral neurons to influence novelty seeking and positive reward traits. Neuropsychopharmacology 41(10):2512-20.
  3. Jobidon L, Jutras-Aswad D (2016). La légalisation du cannabis au Canada: quels enjeux pour la santé mentale? Action-Toxicomanie
  4. Jutras-Aswad D. (2016) Substance use and misuse: emerging epidemiological trends, new definitions, and innovative treatment targets. Canadian journal of Psychiatry 61(3):134-5.
  5. Lévesque A, Roy É, Jutras-Aswad D, Zang G, Artenie AA, Bruneau J (2016). Examining the link between psychological distress, mental health disorders and sharing behaviors among cocaine users. Addictive Behaviors 62:54-9.
  6. Roy E, Arruda N, Bertrand K, Dufour M, Laverdière E, Jutras-Aswad D, Perreault M, Berbiche D, Bruneau J. (2016) Prevalence and correlates of prescription opioid residue injection. Drug and Alcohol Dependence 166:69-74.
  7. Roy É, Arruda N, Bruneau J, Jutras-Aswad D. (2016) Epidemiology of injection drug use: new trends and prominent issues. Canadian journal of Psychiatry 61(3):136-44.
  8. Ouellet-Plamondon C., Dubreucq S, Jutras-Aswad D. (2016) Le sevrage difficile des opioïdes. Le Médecin du Québec 51(11):41-44.
  9. Sacks-Davis R, Daniel M, Roy É, Kestens Y, Zang G, Ramos Y, Hellard M, Jutras Aswad D, Bruneau J (2016). The role of living context in prescription opioid injection and the associated risk of hepatitis C infection. Addiction 111(11):1985-1996.
  1. Artenie AA, Bruneau J, Zang G, Lespérance F, Renaud J, Tremblay J, Jutras-Aswad D. (2015) Associations of substance use patterns with attempted suicide among persons who inject drugs: Can distinct use patterns play a role? Drug and Alcohol Dependence 147: 208-14.
  2. Artenie, A. A, Bruneau J, Roy, É, Zang G, Lespérance, F., Renaud, J., Tremblay, J., and Jutras-Aswad, D. (2015) Licit and illicit substance use among people who inject drugs and the association with subsequent suicidal attempt. Addiction 110(10): 1636–43.
  3. Artenie AA, Jutras-Aswad D, Roy É, Zang G, Bamvita JM, Lévesque A, Bruneau J. (2015) Visits to primary care physicians among persons who inject drugs at high risk of hepatitis C virus infection: room for improvement. Journal of Viral Hepatitis 22(10):792-9.
  4. Artenie AA, Roy E, Zang G, Jutras-Aswad D, Bamvita JM, Puzhko S, Daniel M, Bruneau J. (2015) Hepatitis C virus seroconversion among persons who inject drugs in relation to primary care physician visiting: The potential role of primary healthcare in a combined approach to hepatitis C prevention. International Journal of Drug Policy 26(10):970-5.
  5. Dube E, O’Loughlin J, Karp I, Jutras-Aswad, D. (2015) Cigarette smoking may modify the association between cannabis use and adiposity in males. Pharmacology Biochemistry and Behavior 135:121-7.
  6. Hurd, Y. L., Yoon, M., Manini, A. F., Hernandez, S., Olmedo, R., Ostman, M., Jutras-Aswad, D. (2015) Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage. Neurotherapeutics 12(4):807-15.
  7. Manini AF, Yiannoulos G, Bergamaschi MM, Hernandez S, Olmedo R, Barnes AJ, Winkel G, Sinha R, Jutras-Aswad D, Huestis MA, Hurd YL. (2015) Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. Journal of Addiction Medicine. Journal of Addiction Medicine 9(3):204-10.
  8. Marcaurelle H, Jutras-Aswad D (2015). La psychose toxique: quand les substances jouent avec la tête. Action-Toxicomanie 
  9. Prud’homme M, Cata R, Jutras-Aswad D. (2015) Cannabidiol as an intervention for addictive behaviours: a systematic review of the evidence. Substance Abuse 9:33–38.
  10. Roy É, Jutras-Aswad D, Bertrand K, Dufour M, Perreault M, Laverdière É, Bene-Tchaleu F, Bruneau J. (2015) Anxiety, mood disorders and injection risk behaviors among cocaine users: Results from the COSMO study. The American Journal on Addictions 24(7):654-60.
  11. Thibault A, Brissette S, Jutras-Aswad D. (2015) Systematic review of the pharmacological treatment of alcohol use disorders in individuals infected with hepatitis C. Addiction Science & Clinical Practice 10:6.
  1. Bamvita JM, Roy E, Zang G, Jutras-Aswad D, Artenie AA, Levesque A, Bruneau J. (2014) Portraying persons who inject drugs recently infected with hepatitis C accessing antiviral treatment: a cluster analysisHepatitis Research and Treatment 2014:631481.
  2. Bruneau J, Zang G, Abrahamowicz M, Jutras-Aswad D, Daniel M, Roy E (2014). Sustained drug use changes following hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study. Clinical Infectious Diseases 58(6):755-61.
  3. Clément A, Raymond K, Puzhko S, Bruneau J, Jutras-Aswad D. (2014) Exploration des mécanismes potentiels sous-jacents aux troubles liés à l’utilisation d’une substance chez les personnes atteintes de troubles de la personnalité. Santé Mentale au Québec 39(2): 99-115.
  4. Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D (2014). Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55(6):791-802
  5. Lévesque A, Bruneau J, Jutras-Aswad D, Bertrand K, Chanut F, Dufour M, Lespérance F, Roy E (2014). Psychological distress increases needle sharing among cocaine users: results from the COSMO study. Journal of Addiction Research & Therapy S10:003.
  6. Morrissette A, Ouellet-Plamondon C, Jutras-Aswad D. (2014) Le craving comme symptôme central de la toxicomanie: De ses fondements neurobiologiques à sa pertinence clinique. Santé Mentale au Québec 39(2): 21-37.
  1. Giasson-Gariepy K, Duplan T, Jutras-Aswad D (2013). Neurobiologie de la toxicomanie : de la théorie à la pratique. Écho-Toxico 23(1):2-5.
  2. Giasson-Gariépy K, Jutras-Aswad D (2013). A case of hypomania during nicotine cessation treatment with bupropion. Addiction Science & Clinical Practice 8:22.
  3. Hurd YL, Michaelides M, Miller ML, Jutras-Aswad D (2013). Trajectory of adolescent cannabis use on addiction vulnerability. Neuropharmacology 76 Pt B:416-24.
  4. Olière S, Jolette-Riopelle A, Giasson-Gariepy K, Jutras-Aswad D (2013). Modulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction. Frontiers in Psychiatry 4:109
  5. Rivest J, Jutras-Aswad D, Shapiro P (2013). Treating the “unhealthy alcohol user” on medical wards: beyond withdrawal. Journal of Psychiatric Practice 19(3): 213-26.
  1. Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D (2012). The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction 107(7):1318-27.
  2. Dubreucq S, Chanut F, Jutras-Aswad D (2012). Traitement intégré de la co-morbidité toxicomanie et santé mentale chez les populations urbaines: la situation montréalaise. Santé Mentale au Québec 37(1): 31-46.
  3. Guyon L, Levy J, Jutras-Aswad D (2012). Mot de presentation. Drogues, Santé et Société 11(2):i-iii.
  4. Jutras-Aswad D, Jacobs MM, Yiannoulos G, Roussos P, Bitsios P, Nomura Y, Liu X, Hurd YL (2012). Cannabis-dependence risk relates to synergism between neuroticism and proenkephalin SNPs associated with amygdala gene expression: a case-control study. PLoS One 7(6); e39243.
  5. Jutras-Aswad D, Widlitz M, Scimeca MM (2012). Treatment of buprenorphine precipitated withdrawal: a case report. American Journal on Addictions 21(5):392-3.
  6. Katz CL, Jutras-Aswad D, Kiliman M Pilatowicz I, Akerele E, Marrone K, Ozbay F (2012). Alcohol use in Polish 9/11 responders: implications for cross-cultural treatment. Journal of Psychiatric Practice 18(1): 55-63.
  7. Zhornitsky S, Jutras-Aswad D, Stip E, Rompré PP, Potvin S. (2012) Cocaine and psychosis. Dans: Cocaine abuse: pharmacology, treatment and relapse prevention. Éditeurs: Nova Science Publishers.
  1. Chayer MC, Vieux MG, Bruneau J, Jutras-Aswad D (2011). Traitement intégré de l’hépatite C auprès des personnes avec des troubles concomitants de santé mentale et de dépendance : promouvoir le changement en milieu urbain. Santé Mentale au Québec 36(2): 77-96.
  2. Jacobs MM, Jutras-Aswad D, DiNieri JA, Tomasiewicz HC, Hurd YL. (2011) Genetic and environmental determinants of addiction risk related to impulsivity and its neurobiological substrates. Dans: Inhibitory control and drug abuse prevention: research to translation. Éditeur: M.T. Bardo.
  3. Jutras-Aswad D, Scimeca M (2011). Buprenorphine plasma concentration in the management of opioid dependence. American Journal on Addictions 20(3): 304-5.
  1. Cerimele JM, Stern AP, Jutras-Aswad D (2010). Case report: psychosis following excessive ingestion of energy drinks in a patient with schizophrenia. American Journal of Psychiatry 167(3):353
  2. Jutras-Aswad D, Zang G, Bruneau J (2010). Cannabis use correlates of syringe sharing among injection drug users. American Journal on Addictions 19(3):231-7
  1. Jutras-Aswad D, DiNieri JA, Harkany T, Hurd YL (2009). Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome. European Archives of Psychiatry and Clinical Neuroscience 259(7): 395-412.
  2. Jutras-Aswad D, Bruneau J, Hurd YL (2009). Neurobiologie de la toxicomanie : avancées récentes et nouvelles stratégies d’intervention. Drogues, Santé et Société 8(2): 27-73.